Amundi Asset Management US’s Seres Therapeutics MCRB Stock Holding History

Amundi Asset Management US’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1	Closed	-$1K	–	1563
2020 Q4	$1K	Hold	1	–	–	﹤0.01%	1458
2020 Q3	$1K	Hold	1	–	–	﹤0.01%	1587
2020 Q2	$0	Hold	1	–	–	﹤0.01%	1658
2020 Q1	$0	Hold	1	–	–	﹤0.01%	1639
2019 Q4	$0	Hold	1	–	–	﹤0.01%	1643
2019 Q3	$0	Hold	1	–	–	﹤0.01%	1670
2019 Q2	$0	Hold	1	–	–	﹤0.01%	1690
2019 Q1	$0	Hold	1	–	–	﹤0.01%	1665
2018 Q4	$0	Hold	1	–	–	﹤0.01%	1643
2018 Q3	$0	Hold	1	–	–	﹤0.01%	1631
2018 Q2	$0	Hold	1	–	–	﹤0.01%	1598
2018 Q1	$0	Sell	1 -205	-100%	-$39.3K	﹤0.01%	1571
2017 Q4	$42K	Buy	+206	New	+$42.3K	﹤0.01%	1508

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Amundi Asset Management US's MCRB Position: Q1 2021 in Review

Amundi Asset Management US sold out of Seres Therapeutics (MCRB) in Q1 2021, closing a stake of 1 share — an estimated $1K sold.

Amundi Asset Management US first reported a position in MCRB in Q4 2017 and held it in 13 quarters. The position peaked at $42K in Q4 2017. 152 funds tracked by Wall St. Rank hold MCRB as of Q1 2021.

Amundi Asset Management US reported no remaining Seres Therapeutics position as of Q1 2021 after selling out during the quarter.
Amundi Asset Management US sold 1 Seres Therapeutics share in Q1 2021, an estimated $1K.
Amundi Asset Management US first reported a position in Seres Therapeutics in Q4 2017 and held it in 13 quarters.
Amundi Asset Management US's Seres Therapeutics position peaked at $42K in Q4 2017.
152 funds tracked by Wall St. Rank held Seres Therapeutics as of Q1 2021.

Based on Amundi Asset Management US's 13F filing for Q1 2021, filed 17 May 2021.